Added Value of an Anti-Ebola Serology for the Management of Clinically Suspected Ebola Virus Disease Patients Discharged as Negative in an Epidemic Context
Antoine Nkuba-Ndaye, Daniel Mukadi‐Bamuleka, Junior Bulabula-Penge, Guillaume Thaurignac, François Edidi-Atani, Fabrice Mambu-Mbika, Bernice Danga-Yema, Meris Matondo-Kuamfumu, Eddy Kinganda-Lusamaki, Nella Bisento, Raphaël Lumembe-Numbi, Gabriel Kabamba-Lungenyi, Divine Kitsa-Mutsumbirwa, Nelson Kambale-Sivihwa, François Boillot, Éric Delaporte, Placide Mbala‐Kingebeni, Ahidjo Ayouba, Martine Peeters, Steve Ahuka‐Mundeke
Abstract
BACKGROUND: Survivors from Ebola virus disease (EVD) may be at the origin of EVD resurgence. METHODS: Simultaneous reactivity to at least 2 Ebola virus or Zaire ebolavirus (EBOV) antigens was detected in 11 of 488 (2.3%; 95% confidence interval [CI], 1.1-4.0) suspected EVD patients who were discharged as negative after 2 consecutive negative tests during the 10th Ebola outbreak in the Democratic Republic of the Congo. RESULTS: After extrapolating the total number of individuals discharged as negative during the entire outbreak, we estimated a total of 1314 additional missed Ebola cases. CONCLUSIONS: These findings emphasize the usefulness of an EBOV serology analysis and the importance of extending epidemic surveillance to clinically suspected cases who were discharged as negative.